Importance of Detecting Multidrug Resistance Proteins in Acute Leukemia Prognosis and Therapy

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 1, 2013, Pages 62-71

  de Moraes, Ana Carolina Rabello ^a   Maranho, Caroline Klein ^a   Rauber, Gabriela Schneider ^a   Santos Silva, Maria Cláudia ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

ABCB1; ABCC1; Acute leukemia; LRP; Multidrug resistance

Indexed keywords

ABCC1 PROTEIN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CYTOPLASM; DRUG TRANSPORT; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; CELL LINE, TUMOR; HUMANS; LEUKEMIA; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 84872568083     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21563     Document Type: Article

References (99)

1. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, fourth edition, Geneva: WHO Press; 2008.
2. Gol BJ, Zagozdzon R, Kaminski R, et al. Potentiated antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 2001;15(4):613-620.
3. Filipits M. Mechanism of cancer: Multidrug resistance. Drug Discov Today 2004;1(2):229-234.
4. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000;85:217-229.
5. Krishan A, Arya P. Monitoring of cellular resistance to cancer chemotherapy. Hematol Oncol Clin North Am 2002;16:357-372.
6. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005;14(1):35-48.
7. Van Der Deen M, De Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, Postma DS. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 2005;6:59.
8. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassete (ABC) transporter superfamily. Gen Res 2001;11:1156-1166.
9. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 1976;455:152-162.
10. Fojo AT, Whang-Peng J, Gottesman MM, Pastan I. Amplification of DNA sequences in human multidrug-resistance KB carcinoma cells. Proc Natl Acad Sci USA 1985;83(12):7661-7665.
11. Chen C, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-Glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47(3):381-389.
12. Ohtani H, Ikegawa T, Honda Y, et al. Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-Gp-overexpressing K562/ADM cells. Pharm Res 2007;24(10):1936-1943.
13. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37(6):649-658.
14. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2(1):48-58.
15. Leslie EM, Deeley RG, Cole SPC. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmal 2005;204(3):216-237.
16. Fromn MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and functions in humans. Adv Drug Deliv Rev 2002;54(10):1295-1310.
17. Marzolini C, Paus E, Buclin T, Kim RB. Polimorphisms in human MDR1 (P-glycoprotein) recent advances and clinical relevance. Clin Pharmacol Ther 2004;75(1):13-33.
18. Jonhstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent cell death. Blood 1999;93(3):1075-1085.
19. Balcerkzac E, Panczyk M, Piaskowski S, Walczak GP, Salagacka A, Mirowski M. ABCB1/MDR1 gene polimorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 2010;25(10):1167-1176.
20. Park SW, Lomri N, Simeoni LA, Fruehauf JP, Mechetner E. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Citometry A 2003;53(2):67-78.
21. Kourti M, Vavatsi N, Gombakis N, et al. Expression of multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 2007;86(2):166-173.
22. Litman T, Druley TE, Stein WD, Bates SE. New understanding of multidrug resistance system, their properties and clinical significances. Cell Mol Life Sci 2001;58(7):931-959.
23. Higgins CF. Flip-flop: The transmembrane translocation of lipids. Cell 1994;79(3):393-395.
24. Dawson RJP, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006;443(7108):180-185.
25. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-627.
26. Maia RC, Rumjanek VM. Clinical significance of multidrug resistance in acute leukemias. Rev Assoc Med Bras 1996;42(1):101-108.
27. Pirker R, Wallner T, Geissler K. MDR-1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991;83:708-712.
28. Goasguen JE, Dossot JM, Fardel O. Expression of the multidrug resistance associated p-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia. Prognostic implications. Blood 1993;81:2394-2399.
29. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Ginecol Oncol 2004;93:98-106.
30. Leonessa F, Clarke R. ATP binding cassete transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003;10(1):43-73.
31. Rosenberg MF, Mao Q, Hoszenburgi A, Ford RC, Deeley RG, Cole SPC. The structure of the multidrug resistance protein 1 (MRP1/ABCC1) crystallization and single-particle analysis. J Bioll Chem 2001;278(19):16076-16082.
32. Kruh GD, Zeng H, Rea PA, et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 2001;33(6):493-501.
33. McGrath T, Center MS. Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. Biochem Biophys Res Commun 1987;145(3):1171-1176.
34. Mirski SEL, Gerlach JH, Cole SPC. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987;47(10):2594-2598.
35. Versantvoort CHM, Broxterman HJ, Pinedo HM, et al. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res 1992;52(1):17-23.
36. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650-1654.
37. Borst P, Evers R, Kool M, Wijhholds J. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92(16):1295-1302.
38. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54(2):357-361.
39. Kast C, Gros P. Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence. J Bioll Chem 1997;272(42):26479-26487.
40. Haimeur A, Conseil G, Deeley RG, Cole SP. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol Pharmac 2004;65(6):1375-1385.
41. Hipfner DR, Deeley RG, Cole SPC. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999;1461(2):359-376.
42. Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 2006;27(8):438-446.
43. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999;96(7):3900-3905.
44. St-Pierre MV, Serrano MA, Macias RIR, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol 2000;279(4):R1495-R1503.
45. Mao Q, Deeley RG, Cole SPC. Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. J Bioll Chem 2000;275(44):34166-34172.
46. Wong IL, Faichan K, Tsang KH, et al. Modulation of multidrug resistance protein 1 (MRP/ABCC1) - Mediated multidrug resistance by bivalent apigenin homodimers and there derivatives. J Med Chem 2009;52:5211-5322.
47. Ballatori N, Hammong CL, Cunningham JB, Krance SM, Marchan R. Molecular mechanisms of reduced glutathione transport: Role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxico Ap Pharma 2005;204(3):238-255.
48. Ishikawa T, Bao JJ, Yamane Y, et al. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996;271(25):14981-14988.
49. Kuo MT, Bao J, Furuichi M, et al. Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmaco 1998;55(5):605-615.
50. Berger W, Setinek U, Hollaus P, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small lung cancer: Prognostic implications. J Cancer Res Clin Onco 2005;131:355-363.
51. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger. Clin Cancer Res 2001;7:1798-1804.
52. Munoz M, Henderson M, Haberand M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. Life 2007;59(12):752-757.
53. Plasschaert SL, De Bont ES, Boezen M, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005;11(24):8661-8668.
54. Gottesman NM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Rev Cancer 2002;2:48-58.
55. Mahjoubi F, Golalipour M, Ghavamzadeh A, Alimoghaddam K. Expression of MRP1 gene in acute leukemia. São Paulo Med J 2008;126(3):172-179.
56. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physio Rev 2006;86(3):849-899.
57. Meschini S, Marra M, Calcabrini A, et al. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol in vitro 2002;16:389-398.
58. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. Euro J Cancer 1996;32(6):979-984.
59. Kolli S, Zito CI, Mossink MH, Wiemer EA, Bennett AM. The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. J Biol Chem 2004;279:29374-29385.
60. Kozlov G, Vavelyuk O, Minailiuc CO, Banville D, Gehring K, Ekiel I. Solution structure of a two-repeat fragment of major vault protein. J Mol Biol 2006;356:444-452.
61. Siva AC, Raval-Fernandes S, Stephen AG, et al. Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Internatl J Cancer 2001;92:195-202.
62. Van Zon A, Mossink MH, Schoester M, Scheper RJ, Sonneveld P, Wiemer EA. Efflux kinetics and intracelular distribution of daunorubicin are not affected by major vault protein / lung resistance-related protein (vault) expression. Cancer Res 2004;64:4887-4892.
63. Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippe J. Prognostic significance of multidrug resistance-related proteins in childhood acute lynphoblastic leukaemia. Euro J Cancer 2006;42:295-309.
64. Yasunami T, Wang Y, Tsuji K, Takanashi M, Yamada Y, Motoji T. Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leukemia Res 2007;31:465-470.
65. Sauerbrey A, Voigt A, Wittig S, Hafer R, Zinti F. Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma 2002;43:875-879.
66. Filipts M. Mechanism of cancer: Multidrug resistance. Drug Discov Today 2004;1(2):229-234.
67. Den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998;91:2092-2098.
68. Ramakers-Vanwoerden NL, Beverloo HB, Veerrman AJP, et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004;18:521-529.
69. Ogretmen B, Barredo JC, Safa AR. Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. J Ped Hematol Oncol 2000;22:45-49.
70. Krishan A, Arya P. Monitoring of cellular resistance to cancer chemotherapy. Hematol Oncol Clin North Am 2002;16:357-372.
71. Scherbakova EA, Stromskaya TP, Rybalkina EYU, Kalita OV, Stavrovskaya AA. Role of the PTEN protein in the multidrug resistance of prostate cancer cells. Cell Mol Biol 2008;42(3):430-435.
72. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/AKT/mTOR and Jak/STAT pathways to leukemia signaling and apoptotic pathways and leukemia. Leukemia 2008;22:686-707.
73. Fujimaki S, Funato T, Harigae H. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 2002;48(6):811-817.
74. Dhooge C, De Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study. Br J Haematol 1999;105(3):676-683.
75. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000;85(7):711-721.
76. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2004;128:324-332.
77. Suarez L, Vidriales MV, Garcia-Laraña J, et al. CD34 + Cells from acute myeloid leukemia, myelodysplastic syndromes and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res 2004;10:7599-7606.
78. Valera ET, Scrideli CA, Queiroz RGP, Mari BMO, Tone LG. Multiple drug resistance protein (MDR-1), multidrug resistancerelated protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. São Paulo Med J 2004;122(4):166-171.
79. Benderra S, Faussat AM, Sayada L, et al. MRP3, and P-glycoprotein in activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005;11(21):7764-7772.
80. Olson DP, Taylor BJ, La M, Sather H, Reaman GH, Ivy P. The prognostic significance of P-glycoprotein, multidrug resistancerelated protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: A retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymphoma 2005;45(5):681-691.
81. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Tima S, Chanarat P, Limtrakul P. Inhibitory effect of curcumin on gene expression in patient leukemic cells. Arch Pharm Res 2006;29(10):866-873.
82. Huh HJ, Park CJ, Jang S, et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 2006;21:253-258.
83. Styczynski J, Wysocki M, Debski R, et al. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2007;133:875-893.
84. Fedasenka UU, Shman TV, Savitski VP, Belevsev MV. Expression of MDR1, LRP, BCRP and BCL-2 genes at diagnosis of childhood ALL: Comparison with mrd status after Induction therapy. Expl Oncol 2008;30(3):248-252.
85. Figueiredo-Pontes LF, Pintão MC, Oliveira LCO, et al. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry Part B 2008;74B:163-168.
86. Grotel MV, Van Den Heuvel-Eibrink MM, Van Wering ER, et al. CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. Ped Blood Cancer 2008;51:737-740.
87. Svirnovski A, Shman TV, Serhiyenka T, et al. ABCB1 and ABCG2 proteins, the functional activity and gene expression concert with drug sensitivity of leukemia cells. Hematology 2009;14(4):204-212.
88. El-Sharnouby JA, Abou El-Enein AM, El Ghannam DM, et al. Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia. J Oncol Pharm Pract 2010;16(3):179-188.
89. Chauhan PS, Bhushan B, Singh LC, et al. Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: Response to induction chemotherapy. Exp Mol Pathol 2012;92(1):44-49.
90. Scheiner MAM, Vasconcelos FC, Matta RR, Figueira RDB, Maia RC. ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients. J Cancer Clin Oncol 2012;138(6):959-969.
91. Raaikimakers MHGP, Grouw EPLM, Reijden BAV, Witte TJM, Jansen JH, Raymakers RAP. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin Cancer Res 2006;12(11):3452-3458.
92. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood 1999;94:1086-1099.
93. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010;116:4077-4085.
94. Kolitz JE, George SL, Marcucci G, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116:1413-1421.
95. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: Still a daunting challenge to the successful treatment of AML. Drug Resist Updat 2012;15(1-2):62-69.
96. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 2001;98(12):3212-3220.
97. Liu Yin JA, Wheatley K, Rees JK, Burnett AK. Comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial. Br J Haematol 2001;113(3):713-726.
98. Gerrard G, Payne E, Baker R, et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 2004;89:782-790.
99. Sharom FJ. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomisc 2008;9(1):105-127.